300676 华大基因
2025/06 - 中期2024/122023/122022/122021/12

盈利能力分析
净资产收益率 ROE (%)0.063-9.5050.9328.27819.195
总资产报酬率 ROA (%)0.046-6.9030.6645.60611.486
投入资产回报率 ROIC (%)0.055-8.1810.7766.45113.701

边际利润分析
销售毛利率 (%)44.64641.47249.90352.27358.094
营业利润率 (%)-0.658-22.6223.46315.42426.941
息税前利润/营业总收入 (%)-4.782-24.2171.60114.15527.344
净利润/营业总收入 (%)0.254-23.5872.15411.47421.840

收益指标分析
经营活动净收益/利润总额(%)-590.39044.178206.610115.02096.795
价值变动净收益/利润总额(%)-209.3618.667-28.62638.56014.905
营业外收支净额/利润总额(%)19.3161.281-30.392-8.057-4.407

偿债能力分析
流动比率 (X)2.8132.4192.4062.4713.261
速动比率 (X)2.5802.2082.2232.2903.002
资产负债率 (%)24.80926.07726.51128.94533.764
带息债务/全部投入资本 (%)13.14111.17514.78616.16119.847
股东权益/带息债务 (%)652.593787.159570.761508.284372.023
股东权益/负债合计 (%)298.763279.296273.186242.000193.619
利息保障倍数 (X)1.20618.603-1.518-118.56117.745

营运能力分析
应收账款周转天数 (天)193.850144.749151.33587.48173.815
存货周转天数 (天)115.85895.741109.04185.318119.826